Regina M. DeTore Paglia

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA.

Tufts Associated Health Plans, Inc. provides healthcare plans. It offers health care coverage options to individuals and employer groups. The firm also offers choice tiered network option plan and Steward Community Choice, a community-based plan, developed in conjunction with Steward Health Care System. The company was founded by Morton A. Madoff in 1979 and is headquartered in Watertown, MA.

FMR LLC engages in the provision of financial and investment services. It offers financial planning and advice, wealth management, retirement plans, trading and brokerage services, and investment products. The company was founded by Edward C. Johnson II in 1946 and is headquartered in Boston, MA.

PTTGC Innovation America Corp. engages in the production of bio-based chemical products. Its products include bio-succinic acid, bio-butanediol, and bio-acrylic acid. The company was founded by Stephen J. Gatto in 2004 and is headquartered in Woburn, MA.

Mascoma Corp. develops technology for abundant biomass conversion. The firm operates through its bioprocessing technology platform, develops bioengineered yeasts and other microorganisms. It also designs and manufactures equipment that processes cellulosic biomass for further biological or chemical conversion. The company was founded by Lee R. Lynd, Charles E. Wyman and Robert J. Johnsen in 2005 and is headquartered in Waltham, MA.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.